Skip to content

Escitalopram efficacy on quality of life and prevention of depression in breast cancer patient with mastectomy

Escitalopram efficacy on quality of life and prevention of depression in breast cancer patient with mastectomy

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180421039376N1
Enrollment
75
Registered
2018-05-05
Start date
2018-04-26
Completion date
Unknown
Last updated
2018-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression. Other mental disorders due to known physiological condition

Interventions

Intervention 1: Intervention group: Escitalopram 10 mg tablets start once daily for the first 7 days, followed by increased dose 20 mg (two tablets) daily for the other 11 weeks. Depression and quali

Sponsors

Esfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Women 18-65 y/o Diagnosed with breast cancer stage I,II,IIIa and undergone modified radical mostectomy with or without chemothrapy and radiotherapy Consciously agreement Having at least literacy of writing and reading

Exclusion criteria

Exclusion criteria: Pregnancy and lactation History of conductive heart diseases Severe renal failure Moderate to severe hepatic failure History of SSRI drugs reactions and sensitivity Suffering from depression mood disorders, bipolar disorders or psychotic disorders based on DSM V criteria Any condition limiting life expectancy Any Use of anti depression or anti anxiety drugs since 2 weeks before the study Any precipitation on group or individual psychotherapy sessions since 4 weeks before the study Suffering from any speech disorders Suffering from uncontrolled pain on the beginning of the study Having suicide plans or thoughts on the beginning of the study

Design outcomes

Primary

MeasureTime frame
Depression. Timepoint: 0-4-8-12 week. Method of measurement: DASS questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Zeinolabedini

Esfahan University of Medical Sciences

Z.zeinolabedini@hotmail.com+98 21 4484 1289

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026